Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;137(1):139-49.
doi: 10.1007/s00432-010-0868-x. Epub 2010 Mar 26.

An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus

Affiliations

An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus

De-Xin Lin et al. J Cancer Res Clin Oncol. 2011 Jan.

Abstract

Purpose: Many physicians express a relatively nihilistic approach to the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Consensus among surgeons regarding the indications for an aggressive approach has not been reached. Current study was aimed to determine whether an aggressive approach, with an extended resection with thrombectomy and adjuvant therapy, would lead to an improved survival for HCC patients with PVTT.

Methods: A retrospective review of 116 HCC patients with PVTT admitted from 1996 to 2006 was conducted. Patients were divided into 2 time-period (TP) cohorts, of them, 51 cases in the first 5 years (TP1) and 65 in the last 5 years (TP2).

Results: Surgical operations were performed on 68 patients. Twenty-one surgical resections were performed in TP1 and forty-seven in TP2. The extent of liver resections, as well as the frequency of thrombectomy, was greater in TP2 (P = 0.039). During both time-periods, an aggressive therapy was associated with improved survival (P < 0.02 TP1, P < 0.001 TP2). Overall survival of all patients in TP2 was significantly greater than in TP1 (P < 0.001), with a median survival of 15 months in TP2, whereas in TP1, the survival was only 9 months. The median 1-, 3-year survivals in TP2 (54 and 34%, respectively) were also greater than that in TP1 (31 and 7%, respectively). A multiple logistic regression analysis revealed that radical resection and adjuvant therapy were the independent predictors of overall survival.

Conclusions: An aggressive approach, combining extended liver resection with thrombectomy and adjuvant therapy, leads to an improved survival in the HCC patients with PVTT.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Comparison of the distribution of Vps of disease at presentation between two time-periods
Fig. 2
Fig. 2
Comparison of overall survival between 2 time-periods: Kaplan–Meier curve
Fig. 3
Fig. 3
Effect of liver resection combined with thrombectomy on patients’ survival in TP1 (a) and TP2 (b)
Fig. 4
Fig. 4
Comparison of patients’ survival between Vps in TP1 (a) and TP2 (b)

Similar articles

Cited by

References

    1. Aldrighetti L, Pulitano C, Catena M, Arru M, Guzzetti E, Halliday J, Ferla G (2009) Liver resection with portal vein thrombectomy for hepatocellular carcinoma with vascular invasion. Ann Surg Oncol 16(5):1254. doi:10.1245/s10434-009-0383-y - PubMed
    1. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35(3):519–524. doi:10.1053/jhep.2002.32089 - PubMed
    1. Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, Zhang BX, He SQ, Zhang WG (2006) Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 13(7):940–946. doi:10.1245/ASO.2006.08.007 - PubMed
    1. Chung JW, Park JH, Han JK, Choi BI, Han MC (1995) Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 165(2):315–321 - PubMed
    1. Couinaud C (1994) Intrahepatic anatomy. Application to liver transplantation. Ann Radiol (Paris) 37(5):323–333 - PubMed

MeSH terms